Enliven Therapeutics, Inc. ((ELVN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Enliven Therapeutics, Inc. is conducting a Phase 1a/1b clinical study titled ‘ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer.’ The study aims to evaluate the safety, tolerability, and efficacy of ELVN-002 in patients with HER2 mutant non-small cell lung cancer. This trial is significant as it explores a potential treatment for cancers with HER2 genetic abnormalities, a challenging area in oncology.
The intervention being tested is ELVN-002, an oral capsule designed to target HER2 mutations. The study also explores combinations with other drugs like fam-trastuzumab deruxtecan-nxki and trastuzumab emtansine to assess safety and effectiveness.
The study employs a non-randomized, sequential intervention model. It consists of multiple parts, including dose escalation and expansion phases, to determine optimal dosing and assess the drug’s impact on cancer progression. The primary purpose of the study is treatment-focused, with no masking involved.
The study began on March 20, 2023, and the latest update was submitted on June 27, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
This clinical update could influence Enliven Therapeutics’ stock performance, as positive results may boost investor confidence and position the company favorably against competitors in the oncology market. Investors should watch for further developments, as successful trials could lead to significant market opportunities.
The study is ongoing, with additional details available on the ClinicalTrials portal.